Cancer Immunotherapy Market - Global Outlook and Forecast 2022-2028

March 2022 | 64 pages | ID: C5B7E102E7C4EN
Market Monitor Global

Abstracts

Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer.

This report contains market size and forecasts of Cancer Immunotherapy in Global, including the following market information:

Global Cancer Immunotherapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Cancer Immunotherapy market was valued at 78150 million in 2021 and is projected to reach US$ 131790 million by 2028, at a CAGR of 7.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cancer Immunotherapy include Amgen, AstraZeneca, Roche, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis and Pfizer. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cancer Immunotherapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Cancer Immunotherapy Market Segment Percentages, by Type, 2021 (%)

• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Immune System Modulators
• Cancer Vaccines

Global Cancer Immunotherapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Cancer Immunotherapy Market Segment Percentages, by Application, 2021 (%)

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Others

Global Cancer Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Cancer Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cancer Immunotherapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Cancer Immunotherapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Amgen
• AstraZeneca
• Roche
• Bayer
• Bristol-Myers Squibb
• Eli Lilly
• Merck
• Novartis
• Pfizer

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Cancer Immunotherapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Cancer Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CANCER IMMUNOTHERAPY OVERALL MARKET SIZE

2.1 Global Cancer Immunotherapy Market Size: 2021 VS 2028
2.2 Global Cancer Immunotherapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Cancer Immunotherapy Players in Global Market
3.2 Top Global Cancer Immunotherapy Companies Ranked by Revenue
3.3 Global Cancer Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Cancer Immunotherapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cancer Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cancer Immunotherapy Players in Global Market
  3.6.1 List of Global Tier 1 Cancer Immunotherapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Cancer Immunotherapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Cancer Immunotherapy Market Size Markets, 2021 & 2028
  4.1.2 Monoclonal Antibodies
  4.1.3 Immune Checkpoint Inhibitors
  4.1.4 Immune System Modulators
  4.1.5 Cancer Vaccines
4.2 By Type - Global Cancer Immunotherapy Revenue & Forecasts
  4.2.1 By Type - Global Cancer Immunotherapy Revenue, 2017-2022
  4.2.2 By Type - Global Cancer Immunotherapy Revenue, 2023-2028
  4.2.3 By Type - Global Cancer Immunotherapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Cancer Immunotherapy Market Size, 2021 & 2028
  5.1.2 Lung Cancer
  5.1.3 Breast Cancer
  5.1.4 Colorectal Cancer
  5.1.5 Melanoma
  5.1.6 Prostate Cancer
  5.1.7 Others
5.2 By Application - Global Cancer Immunotherapy Revenue & Forecasts
  5.2.1 By Application - Global Cancer Immunotherapy Revenue, 2017-2022
  5.2.2 By Application - Global Cancer Immunotherapy Revenue, 2023-2028
  5.2.3 By Application - Global Cancer Immunotherapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Cancer Immunotherapy Market Size, 2021 & 2028
6.2 By Region - Global Cancer Immunotherapy Revenue & Forecasts
  6.2.1 By Region - Global Cancer Immunotherapy Revenue, 2017-2022
  6.2.2 By Region - Global Cancer Immunotherapy Revenue, 2023-2028
  6.2.3 By Region - Global Cancer Immunotherapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Cancer Immunotherapy Revenue, 2017-2028
  6.3.2 US Cancer Immunotherapy Market Size, 2017-2028
  6.3.3 Canada Cancer Immunotherapy Market Size, 2017-2028
  6.3.4 Mexico Cancer Immunotherapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Cancer Immunotherapy Revenue, 2017-2028
  6.4.2 Germany Cancer Immunotherapy Market Size, 2017-2028
  6.4.3 France Cancer Immunotherapy Market Size, 2017-2028
  6.4.4 U.K. Cancer Immunotherapy Market Size, 2017-2028
  6.4.5 Italy Cancer Immunotherapy Market Size, 2017-2028
  6.4.6 Russia Cancer Immunotherapy Market Size, 2017-2028
  6.4.7 Nordic Countries Cancer Immunotherapy Market Size, 2017-2028
  6.4.8 Benelux Cancer Immunotherapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Cancer Immunotherapy Revenue, 2017-2028
  6.5.2 China Cancer Immunotherapy Market Size, 2017-2028
  6.5.3 Japan Cancer Immunotherapy Market Size, 2017-2028
  6.5.4 South Korea Cancer Immunotherapy Market Size, 2017-2028
  6.5.5 Southeast Asia Cancer Immunotherapy Market Size, 2017-2028
  6.5.6 India Cancer Immunotherapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Cancer Immunotherapy Revenue, 2017-2028
  6.6.2 Brazil Cancer Immunotherapy Market Size, 2017-2028
  6.6.3 Argentina Cancer Immunotherapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Cancer Immunotherapy Revenue, 2017-2028
  6.7.2 Turkey Cancer Immunotherapy Market Size, 2017-2028
  6.7.3 Israel Cancer Immunotherapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Cancer Immunotherapy Market Size, 2017-2028
  6.7.5 UAE Cancer Immunotherapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Amgen
  7.1.1 Amgen Corporate Summary
  7.1.2 Amgen Business Overview
  7.1.3 Amgen Cancer Immunotherapy Major Product Offerings
  7.1.4 Amgen Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.1.5 Amgen Key News
7.2 AstraZeneca
  7.2.1 AstraZeneca Corporate Summary
  7.2.2 AstraZeneca Business Overview
  7.2.3 AstraZeneca Cancer Immunotherapy Major Product Offerings
  7.2.4 AstraZeneca Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.2.5 AstraZeneca Key News
7.3 Roche
  7.3.1 Roche Corporate Summary
  7.3.2 Roche Business Overview
  7.3.3 Roche Cancer Immunotherapy Major Product Offerings
  7.3.4 Roche Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.3.5 Roche Key News
7.4 Bayer
  7.4.1 Bayer Corporate Summary
  7.4.2 Bayer Business Overview
  7.4.3 Bayer Cancer Immunotherapy Major Product Offerings
  7.4.4 Bayer Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.4.5 Bayer Key News
7.5 Bristol-Myers Squibb
  7.5.1 Bristol-Myers Squibb Corporate Summary
  7.5.2 Bristol-Myers Squibb Business Overview
  7.5.3 Bristol-Myers Squibb Cancer Immunotherapy Major Product Offerings
  7.5.4 Bristol-Myers Squibb Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.5.5 Bristol-Myers Squibb Key News
7.6 Eli Lilly
  7.6.1 Eli Lilly Corporate Summary
  7.6.2 Eli Lilly Business Overview
  7.6.3 Eli Lilly Cancer Immunotherapy Major Product Offerings
  7.6.4 Eli Lilly Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.6.5 Eli Lilly Key News
7.7 Merck
  7.7.1 Merck Corporate Summary
  7.7.2 Merck Business Overview
  7.7.3 Merck Cancer Immunotherapy Major Product Offerings
  7.7.4 Merck Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.7.5 Merck Key News
7.8 Novartis
  7.8.1 Novartis Corporate Summary
  7.8.2 Novartis Business Overview
  7.8.3 Novartis Cancer Immunotherapy Major Product Offerings
  7.8.4 Novartis Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.8.5 Novartis Key News
7.9 Pfizer
  7.9.1 Pfizer Corporate Summary
  7.9.2 Pfizer Business Overview
  7.9.3 Pfizer Cancer Immunotherapy Major Product Offerings
  7.9.4 Pfizer Cancer Immunotherapy Revenue in Global Market (2017-2022)
  7.9.5 Pfizer Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cancer Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Cancer Immunotherapy Market Drivers in Global Market
Table 3. Cancer Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Cancer Immunotherapy in Global Market
Table 5. Top Cancer Immunotherapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Cancer Immunotherapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Cancer Immunotherapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Cancer Immunotherapy Product Type
Table 9. List of Global Tier 1 Cancer Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Cancer Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Cancer Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Cancer Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Cancer Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Cancer Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Cancer Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Cancer Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Cancer Immunotherapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Cancer Immunotherapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Cancer Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Cancer Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Cancer Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Cancer Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Cancer Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Cancer Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Cancer Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Cancer Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Cancer Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Cancer Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 30. Amgen Corporate Summary
Table 31. Amgen Cancer Immunotherapy Product Offerings
Table 32. Amgen Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 33. AstraZeneca Corporate Summary
Table 34. AstraZeneca Cancer Immunotherapy Product Offerings
Table 35. AstraZeneca Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 36. Roche Corporate Summary
Table 37. Roche Cancer Immunotherapy Product Offerings
Table 38. Roche Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 39. Bayer Corporate Summary
Table 40. Bayer Cancer Immunotherapy Product Offerings
Table 41. Bayer Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Corporate Summary
Table 43. Bristol-Myers Squibb Cancer Immunotherapy Product Offerings
Table 44. Bristol-Myers Squibb Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 45. Eli Lilly Corporate Summary
Table 46. Eli Lilly Cancer Immunotherapy Product Offerings
Table 47. Eli Lilly Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 48. Merck Corporate Summary
Table 49. Merck Cancer Immunotherapy Product Offerings
Table 50. Merck Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 51. Novartis Corporate Summary
Table 52. Novartis Cancer Immunotherapy Product Offerings
Table 53. Novartis Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 54. Pfizer Corporate Summary
Table 55. Pfizer Cancer Immunotherapy Product Offerings
Table 56. Pfizer Cancer Immunotherapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Cancer Immunotherapy Segment by Type in 2021
Figure 2. Cancer Immunotherapy Segment by Application in 2021
Figure 3. Global Cancer Immunotherapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Cancer Immunotherapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cancer Immunotherapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cancer Immunotherapy Revenue in 2021
Figure 8. By Type - Global Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 12. US Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 16. Germany Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 24. China Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 30. Brazil Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Cancer Immunotherapy Revenue Market Share, 2017-2028
Figure 33. Turkey Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Cancer Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 37. Amgen Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AstraZeneca Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bayer Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Eli Lilly Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Novartis Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Pfizer Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)